Could a mutation involved in alcohol metabolism contribute to Alzheimer’s disease?
A common mutation in a key enzyme involved in alcohol metabolism may increase damage in cells obtained from individuals with Alzheimer’s disease and in mice.
Browsing: Alzheimer’s disease
Aducanumab update: detailed data reported on ‘resurrected’ Alzheimer’s drug
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
Artificial neurons developed that may help combat chronic diseases, such as Alzheimer’s
Artificial neurons have been developed in a first-of-its-kind achievement that closely resemble biological neurons, mimicking their responses to a range of stimulations.
Sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model: an interview with Hemraj Dodiya
At SfN Neuroscience 2019, we had the brilliant opportunity of interviewing Hemraj Dodiya about sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model.
Tau inhibitor may block self-association and fibril formation in mice
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
Translating genetic data in Alzheimer’s into potential therapies with Owen Peters
What are the challenges associated with identifying risk genes for Alzheimer’s disease? What more needs to be done to successfully translate this genetic data into potential therapeutics? Watch our video with Owen Peters to find out more.
Alzheimer’s and AMD: could elovanoids be a new therapeutic target?
A research team have discovered a new mechanism by which elovanoids may protect retinal and brain cells against neurodegenerative diseases such as Alzheimer’s and age-related macular degeneration.
Circadian disruption in the prodromal stages of dementia with Marco Brancaccio
What might the mechanisms behind circadian dysfunction in the early stages of dementia be? What more needs to be done to successfully translate this into the clinic? Watch our video with Marco Brancaccio to find out.
Highlights from the UK–Korea Neuroscience Symposium with Justin Lee
At the UK–Korea Neuroscience Symposium (12–13 August, London, UK), we had the fantastic opportunity of…
Oligomannate approved for mild-to-moderate Alzheimer’s disease in China
Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.
